1Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy- induced acute liver failure : magnitude, profile, prognosis, and predictors of outcome. Hepatology, 2010, 51 (5) : 1665-1674.
2Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis, 2009, 49(12) : 1883-1889.
3Tostmann A, Boeree M J, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastro- enterol Hepatol, 2008, 23 (2) : 192-202.
4Ho CC, Chen YC, Hu FC, et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis, 2009, 48(11 ) : 1526-1533.
5Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest, 2005, 128(3) : 1406-1413.
